The involvement of IL-1 in the pathogenesis of DIRA prompted to the use of IL-1 inhibitors (i.e.: anakinra, rilonacept and canakinumab) with dramatic results and complete remission of the symptoms as previously reported [2, 3]. Here, IL1A is linked to sterile multifocal osteomyelitis with periostitis and pustulosis.